Keros Therapeutics, Inc.
KROS
$14.91
$0.151.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -30.70M | 148.45M | -46.03M | -52.96M | -45.26M |
| Total Depreciation and Amortization | 370.00K | 344.00K | 332.00K | 314.00K | 306.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.12M | 9.45M | 9.77M | 9.38M | 9.13M |
| Change in Net Operating Assets | -8.42M | 2.93M | -10.09M | 12.76M | -3.98M |
| Cash from Operations | -29.62M | 161.17M | -46.01M | -30.50M | -39.80M |
| Capital Expenditure | -720.00K | -565.00K | -289.00K | -386.00K | -310.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -720.00K | -565.00K | -289.00K | -386.00K | -310.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 17.00K | 4.00K | 75.54M | 156.07M | 3.60M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | -130.00K | -65.00K |
| Cash from Financing | 17.00K | 4.00K | 75.54M | 155.94M | 3.53M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -30.33M | 160.61M | 29.25M | 125.06M | -36.58M |